We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Affymetrix, BioRealm, RUCDR Ally
News

Affymetrix, BioRealm, RUCDR Ally

Affymetrix, BioRealm, RUCDR Ally
News

Affymetrix, BioRealm, RUCDR Ally

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affymetrix, BioRealm, RUCDR Ally "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The samples will be genotyped using the BioRealm SmokeScreen array, a genome-wide array that looks at more than 1,000 addiction-related genes and which was developed in conjunction with NIDA's Genetics Consortium and Affymetrix.

"Because of the SmokeScreen array, we have the ability to reveal genetic information previously hidden in NIDA's samples," RUCDR COO Andrew Brooks said in a statement. "It is a validated platform that will become a crucial tool in advancing addiction research and moving the field towards personalized treatment."

The NIDA biobank contains more than 50,000 samples collected from human subjects in agency-funded research, and is maintained at Rutgers University by RUCDR, a unit of the school's Human Genetics Institute of New Jersey. In May of 2014, RUCDR received at $19 million grant to expand the services it provides to NIDA scientists.

Advertisement